CN117159674B - Gynecological traditional Chinese medicine composition for treating damp-heat stasis syndrome - Google Patents
Gynecological traditional Chinese medicine composition for treating damp-heat stasis syndrome Download PDFInfo
- Publication number
- CN117159674B CN117159674B CN202311451517.8A CN202311451517A CN117159674B CN 117159674 B CN117159674 B CN 117159674B CN 202311451517 A CN202311451517 A CN 202311451517A CN 117159674 B CN117159674 B CN 117159674B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- root
- dandelion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 206010041956 Stasis syndrome Diseases 0.000 title abstract description 8
- 208000005634 blind loop syndrome Diseases 0.000 title abstract description 8
- 241000792859 Enema Species 0.000 claims abstract description 34
- 239000007920 enema Substances 0.000 claims abstract description 34
- 229940095399 enema Drugs 0.000 claims abstract description 34
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 18
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims abstract description 17
- 241000913745 Spatholobus Species 0.000 claims abstract description 17
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 16
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 16
- 240000004510 Agastache rugosa Species 0.000 claims abstract description 15
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 15
- 230000001684 chronic effect Effects 0.000 claims abstract description 13
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 235000006533 astragalus Nutrition 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 35
- 241000245665 Taraxacum Species 0.000 claims description 17
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 10
- 241001106477 Paeoniaceae Species 0.000 claims description 10
- 241000045403 Astragalus propinquus Species 0.000 claims description 9
- 240000009138 Curcuma zedoaria Species 0.000 claims description 6
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 6
- 235000019509 white turmeric Nutrition 0.000 claims description 6
- 244000148137 Patrinia villosa Species 0.000 claims description 5
- 235000019109 Patrinia villosa Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 241000132012 Atractylodes Species 0.000 claims description 3
- 241000212322 Levisticum officinale Species 0.000 claims description 3
- 229940107666 astragalus root Drugs 0.000 claims description 3
- 239000001645 levisticum officinale Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 235000005412 red sage Nutrition 0.000 claims 4
- 244000153955 Reynoutria sachalinensis Species 0.000 claims 2
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 16
- 235000017276 Salvia Nutrition 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 210000004696 endometrium Anatomy 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000000509 infertility Diseases 0.000 abstract description 5
- 230000036512 infertility Effects 0.000 abstract description 5
- 231100000535 infertility Toxicity 0.000 abstract description 5
- 208000025661 ovarian cyst Diseases 0.000 abstract description 5
- 208000005641 Adenomyosis Diseases 0.000 abstract description 4
- 208000028685 Asherman syndrome Diseases 0.000 abstract description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract description 4
- 206010034238 Pelvic adhesions Diseases 0.000 abstract description 4
- 201000001389 adhesions of uterus Diseases 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 201000009274 endometriosis of uterus Diseases 0.000 abstract description 4
- 230000016087 ovulation Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000002054 transplantation Methods 0.000 abstract description 4
- 208000037063 Thinness Diseases 0.000 abstract description 3
- 230000010412 perfusion Effects 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 23
- 239000008187 granular material Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 208000011580 syndromic disease Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 210000002255 anal canal Anatomy 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 241001529821 Agastache Species 0.000 description 3
- 235000014375 Curcuma Nutrition 0.000 description 3
- 244000164480 Curcuma aromatica Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 235000005206 Hibiscus Nutrition 0.000 description 2
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 2
- 241001162994 Rugosus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010052489 Abdominal rebound tenderness Diseases 0.000 description 1
- 206010000097 Abdominal tenderness Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 244000130592 Hibiscus syriacus Species 0.000 description 1
- 235000018081 Hibiscus syriacus Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046827 Uterine tenderness Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- CAOOISJXWZMLBN-PPHPATTJSA-N htn0d03vrz Chemical compound Cl.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 CAOOISJXWZMLBN-PPHPATTJSA-N 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a gynaecologic traditional Chinese medicine composition for treating damp-heat stasis syndrome, which comprises herba patriniae, dandelion, polygonum cuspidatum, spatholobus stem, ligusticum wallichii, root of red-rooted salvia, rhizoma curcumae, rhizoma atractylodis, radix paeoniae rubra, wrinkled gianthyssop and raw astragalus. The gynecological traditional Chinese medicine composition has the effects of resolving dampness, clearing heat, promoting blood circulation and removing blood stasis, and can be used for treating chronic pelvic inflammatory disease, pelvic inflammatory disease sequelae, repeated transplantation failure, hydrotubation, intrauterine adhesion, endometrium blood flow perfusion failure, endometrium thinness, adenomyosis, secondary dysmenorrhea, infertility, ovarian cyst, ovulation promotion, pelvic adhesion prevention after gynecological operation and other diseases. The invention also protects enema and rectal administration preparation prepared from the traditional Chinese medicine composition and application thereof.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a gynecological traditional Chinese medicine composition for treating damp-heat stasis syndrome, enema and rectal administration preparation.
Background
Pelvic inflammatory disease refers to inflammatory diseases of female upper genital tract and surrounding tissues, including endometritis and oviduct ovarian cyst, and can develop into chronic if the acute phase is not prolonged, resulting in chronic pelvic pain, oviduct pregnancy, and even infertility. The clinical application mostly adopts antibiotics to treat, but most of chronic pelvic inflammatory disease is mixed infection, the treatment effect of single antibiotics is poor, and the antibiotics are easy to generate drug resistance and dysbacteriosis after long-term use, and the recurrence rate is high.
The traditional Chinese medicine oral administration has the first pass elimination effect, influences the exertion of the drug effect, and is easy to cause adverse reactions such as diarrhea, allergy and the like due to compatibility and formulation problems of the existing enema medicines on the market.
Disclosure of Invention
The first aim of the invention is to provide a gynecological traditional Chinese medicine composition for preparing a medicine for treating damp-heat stasis syndrome, which comprises herba patriniae, dandelion, polygonum cuspidatum, caulis spatholobi, ligusticum wallichii, radix salviae miltiorrhizae, rhizoma curcumae, rhizoma atractylodis, radix paeoniae rubra, wrinkled gianthyssop and radix astragali.
1-20 parts of herba patriniae, 1-20 parts of dandelion, 1-30 parts of polygonum cuspidatum, 1-20 parts of spatholobus stem, 1-20 parts of ligusticum wallichii, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of rhizoma curcumae, 1-20 parts of rhizoma atractylodis, 1-20 parts of radix paeoniae rubra, 1-30 parts of wrinkled gianthyssop and 1-30 parts of raw astragalus membranaceus.
10 parts of herba patriniae, 10 parts of dandelion, 15 parts of polygonum cuspidatum, 10 parts of spatholobus stem, 10 parts of ligusticum wallichii, 10 parts of root of red-rooted salvia, 10 parts of curcuma zedoary, 10 parts of rhizoma atractylodis, 10 parts of red paeony root, 15 parts of wrinkled gianthyssop and 15 parts of raw astragalus membranaceus.
The gynaecologic traditional Chinese medicine composition also comprises Dai medicine Luo Mailiang Dragon and Zhongzheng.
1-20 parts of herba patriniae, 1-20 parts of dandelion, 1-30 parts of polygonum cuspidatum, 1-20 parts of spatholobus stem, 1-20 parts of ligusticum wallichii, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of rhizoma curcumae, 1-20 parts of rhizoma atractylodis, 1-20 parts of radix paeoniae rubra, 1-30 parts of agastache rugosus, 1-30 parts of radix astragali, 1-20 parts of Luo Mailiang dragon and 2-10 parts of Chinese boat.
10 parts of herba patriniae, 10 parts of dandelion, 15 parts of polygonum cuspidatum, 10 parts of spatholobus stem, 10 parts of ligusticum wallichii, 10 parts of root of red-rooted salvia, 10 parts of rhizoma curcumae, 10 parts of rhizoma atractylodis, 10 parts of red paeony root, 15 parts of wrinkled gianthyssop herb, 15 parts of raw astragalus mongholicus, 10 parts of Luo Mailiang dragon and 10 parts of Chinese boat.
The second aim of the invention is to provide an enema liquid of a gynecological traditional Chinese medicine composition for preparing a medicine for treating damp-heat stasis syndrome, which consists of a granule medicine box and an enema bag, wherein the granule medicine box is provided with small lattices, and each small lattice is respectively used for storing the medicinal material granules.
The preparation method of the enema liquid comprises the steps of opening all small lattices in a granule medicine box, pouring out the medicine, placing the medicine in a proper container, adding 100-150 mL of warm water, uniformly stirring, and then injecting the medicine into an enema bag.
The temperature of the warm water is 37-45 ℃.
The enema of the gynecological traditional Chinese medicine composition is applied to the preparation of medicines for treating chronic pelvic inflammatory disease, sequelae of pelvic inflammatory disease, repeated transplantation failure, hydrotubation, intrauterine adhesion, endometrium blood flow perfusion failure, endometrium thinness, adenomyosis, secondary dysmenorrhea, infertility, ovarian cyst, ovulation promotion, pelvic adhesion prevention after gynecological operation and other diseases.
The third purpose of the invention is to provide a rectal administration preparation of the gynecological traditional Chinese medicine composition, which is prepared by adding pharmaceutically acceptable auxiliary materials.
The Luo Mailiang dragon related by the invention is Dai medicine and is also called as hibiscus.
The Chinese voyage related by the invention is Dai medicine, which is also called double-seed brown.
The invention has the advantages that:
the invention provides a gynaecologic traditional Chinese medicine composition for treating damp-heat stasis syndrome, which is prepared into enema liquid and clinically used for treating chronic pelvic inflammatory disease, sequelae of pelvic inflammatory disease, repeated transplantation failure, hydrotubation, intrauterine adhesion, poor endomembrane blood perfusion, endometrium thin, adenomyosis, secondary dysmenorrhea, infertility, ovarian cyst, ovulation promotion, pelvic adhesion prevention after gynaecologic operation and other diseases.
Herba Patriniae has effects of clearing heat and detoxicating, resolving carbuncle and expelling pus, dandelion has effects of resolving carbuncle and resolving hard mass, polygonum cuspidatum and spatholobus stem have effects of dispelling wind and removing stasis, clearing heat and promoting diuresis, ligusticum wallichii and radix salviae miltiorrhizae have effects of promoting blood circulation and removing stasis, rhizoma curcumae and rhizoma atractylodis have effects of promoting qi and eliminating dampness, promoting blood circulation and relieving pain, radix paeoniae rubra has effects of clearing heat and cooling blood, removing stasis and relieving pain, herba agastachis has effects of removing dampness and promoting qi, radix astragali has effects of invigorating qi and strengthening exterior, luo Mailiang has effects of dispelling wind and removing toxicity, promoting blood circulation and relieving pain, and has effects of stopping bleeding and clearing heat, dredging channels and astringing.
The enema related to the invention has the advantages of reducing the first pass effect of the liver and reducing the side effect on the liver. The medicine directly enters the pelvic venous plexus after absorption, the local medicine concentration is higher, the treatment effect is enhanced, the action time is long, and the bioavailability is high.
Detailed Description
The invention is further described below without limiting it in any way, and any modifications based on the invention fall within the scope of protection of the invention.
A gynecological Chinese medicinal composition for preparing medicine for treating damp heat stagnation syndrome comprises herba Patriniae, herba Taraxaci, rhizoma Polygoni Cuspidati, caulis Spatholobi, rhizoma Ligustici Chuanxiong, saviae Miltiorrhizae radix, curcumae rhizoma, rhizoma Atractylodis, radix Paeoniae Rubra, herba Agastaches, and radix astragali.
1-20 parts of herba patriniae, 1-20 parts of dandelion, 1-30 parts of polygonum cuspidatum, 1-20 parts of spatholobus stem, 1-20 parts of ligusticum wallichii, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of rhizoma curcumae, 1-20 parts of rhizoma atractylodis, 1-20 parts of radix paeoniae rubra, 1-30 parts of wrinkled gianthyssop and 1-30 parts of raw astragalus membranaceus.
10 parts of herba patriniae, 10 parts of dandelion, 15 parts of polygonum cuspidatum, 10 parts of spatholobus stem, 10 parts of ligusticum wallichii, 10 parts of root of red-rooted salvia, 10 parts of curcuma zedoary, 10 parts of rhizoma atractylodis, 10 parts of red paeony root, 15 parts of wrinkled gianthyssop and 15 parts of raw astragalus membranaceus.
The gynaecologic traditional Chinese medicine composition also comprises Dai medicine Luo Mailiang Dragon and Zhongzhuang, namely Patrinia, dandelion, polygonum cuspidatum, suberect spatholobus stem, szechuan lovage rhizome, red-rooted salvia root, zedoary, swordlike atractylodes rhizome, red paeony root, wrinkled gianthyssop herb, raw astragalus root, luo Mailiang Dragon and Zhongzhuang.
1-20 parts of herba patriniae, 1-20 parts of dandelion, 1-30 parts of polygonum cuspidatum, 1-20 parts of spatholobus stem, 1-20 parts of ligusticum wallichii, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of rhizoma curcumae, 1-20 parts of rhizoma atractylodis, 1-20 parts of radix paeoniae rubra, 1-30 parts of agastache rugosus, 1-30 parts of radix astragali, 1-20 parts of Luo Mailiang dragon and 2-10 parts of Chinese boat.
10 parts of herba patriniae, 10 parts of dandelion, 15 parts of polygonum cuspidatum, 10 parts of spatholobus stem, 10 parts of ligusticum wallichii, 10 parts of root of red-rooted salvia, 10 parts of rhizoma curcumae, 10 parts of rhizoma atractylodis, 10 parts of red paeony root, 15 parts of wrinkled gianthyssop herb, 15 parts of raw astragalus mongholicus, 10 parts of Luo Mailiang dragon and 10 parts of Chinese boat.
The enema liquid of the gynecological traditional Chinese medicine composition consists of a granule medicine box and an enema bag, wherein the granule medicine box is provided with small lattices, and each small lattice is respectively used for storing medicinal granules.
The preparation method of the enema liquid comprises the steps of opening all small lattices in a granule medicine box, pouring out the medicine, placing the medicine in a proper container, adding 100-150 mL of warm water, uniformly stirring, and then injecting the medicine into an enema bag.
The temperature of the warm water is 37-45 ℃.
The rectal administration preparation of the gynecological traditional Chinese medicine composition is prepared by adding pharmaceutically acceptable auxiliary materials.
The enema of the gynecological traditional Chinese medicine composition is applied to the preparation of medicines for treating chronic pelvic inflammatory disease, sequelae of pelvic inflammatory disease, repeated transplantation failure, hydrotubation, intrauterine adhesion, endometrium blood flow perfusion failure, endometrium thinness, adenomyosis, secondary dysmenorrhea, infertility, ovarian cyst, ovulation promotion, pelvic adhesion prevention after gynecological operation and other diseases.
The Luo Mailiang dragon related by the invention is Dai medicine and is also called as hibiscus.
The Chinese voyage related by the invention is Dai medicine, which is also called double-seed brown.
Example 1:
10g of herba patriniae, 10g of dandelion, 15g of polygonum cuspidatum, 10g of suberect spatholobus stem, 10g of ligusticum wallichii, 10g of root of red-rooted salvia, 10g of curcuma zedoary, 10g of rhizoma atractylodis, 10g of red paeony root, 15g of wrinkled gianthyssop herb and 15g of raw astragalus membranaceus.
Example 2:
10g of herba patriniae, 10g of dandelion, 15g of polygonum cuspidatum, 10g of spatholobus stem, 10g of ligusticum wallichii, 10g of root of red-rooted salvia, 10g of rhizoma curcumae, 10g of rhizoma atractylodis, 10g of red paeonia, 15g of wrinkled gianthyssop, 15g of raw astragalus mongholicus, 10g of Luo Mailiang dragon (Dai medicine, shrubalthea) and 10g of Chinese navigation (Dai medicine, double seed brown).
Example 3:
the operation flow of traditional Chinese medicine retention enema comprises the following steps:
the traditional Chinese medicine observation components: a first part: a granule medicine box. The traditional Chinese medicine particles described in the embodiment 1 are filled in the medicine box. The amount of the medicine in one box is once, all the small lattices of the box are opened, the medicine is poured out and put into a proper container, 100-150 mL of warm water is added, and the medicine is slightly higher than the body temperature and is not scalded. A second part: enema bags (similar to infusion bags).
The steps are as follows: (1) The valve of the enema bag is completely closed (the position of the infusion bag for adjusting the dripping speed at ordinary times); (2) Pouring the medicine which is prepared by warm water in the first part from the upper opening of the enema bag (provided that the valve is completely closed); (3) The person adopts a lying or side lying position, hangs the enema bag to a position higher than the level of the person, coats 10-15 cm of the tube at the tail end of the enema bag with lubricant (vaseline, glycerol and the like), then slowly places the tube into anus (not vagina), and slowly opens the valve of the enema bag to enable the prepared medicament to flow into the body. (4) After entering the body, the medicine is laid on the bed as much as possible, so that the medicine is kept in the body for at least 30 minutes, and can be kept in the morning the next day and discharged during the toilet when the medicine is prepared. (5) If the medicine is kept for the next day, the toilet finds that the stool is thin, and the medicine is not stressed, which is a normal phenomenon.
Notice matters
1. When the anal canal is inserted, the action should be kept gentle, if the patient has uncomfortable feeling or has resistance, the patient should gently massage the anus periphery, and slowly insert the anal canal after the anal canal is relaxed or is free from resistance, and the anal canal should not be forcibly inserted.
2. When the enema bag is extruded to inject the liquid medicine, the reaction of the patient is closely observed at a constant speed, if the patient is uncomfortable, the injection speed is slowed down or the injection is paused, and after the uncomfortable feeling of the patient disappears, the injection is slowly extruded.
3. During the enema, the patient should be closely observed, such as pale complexion, palpitation, sweats, dizziness, etc., and should be immediately stopped for symptomatic treatment.
4. After the enema operation is finished, the patient should keep lying, and continue to observe, and the patient is recommended to be best accompanied by a person.
5. If the patient suffers from hemorrhoids, especially when the patient is operated, the patient needs to pay attention to preventing the bleeding from touching, and the enema treatment is not given once in the acute onset period or the severe symptoms of hemorrhoids.
Clinical efficacy evaluation:
the enema formula for resolving dampness and removing blood stasis is self-simulated and preliminarily proves that the enema formula can improve the integral of the pelvic cavity physical sign scale (McCormack), the integral of the McGill pain scale, the integral of the traditional Chinese medicine symptoms and the serum inflammatory factor level of a patient with chronic pelvic inflammatory disease, and the report is as follows.
1 clinical data
1.1 general data
The method includes the steps of recruiting patients meeting the diagnosis standard of chronic pelvic inflammatory disease from the first affiliated hospital reproductive medicine department of Yunnan traditional Chinese medicine university, the outpatient service of the first affiliated hospital acupuncture department of Yunnan traditional Chinese medicine university and the department of clinical reproduction of the second people hospital of Yunnan province from 1 month 1 day to 2023 month 3 days, and distinguishing the symptoms of the traditional Chinese medicine into 30 cases of a control group and a traditional Chinese medicine group at random, wherein the 30 cases are totally included.
1.2 diagnostic criteria
(1) Western diagnostic criteria: the diagnosis standard of chronic pelvic inflammatory disease in gynaecology and obstetrics science is met, wherein the history of acute pelvic inflammatory disease is available, the pain and lumbosacral ache are accompanied with lower abdomen distension and pain, irregular menstruation, leucorrhea are more, the abnormal smell is present, the uterine movement is limited or adhesion is fixed, the pain is accompanied with pressure, the accessory area is pressure, and the ultrasonic examination can detect the thickening of the fallopian tube, the pelvic effusion or the pelvic inflammatory mass.
(2) Traditional Chinese medicine dialectical standard: syndrome differentiation criteria of damp-heat stasis syndrome: main symptoms are as follows: lumbosacral, lower abdominal distending pain or stinging pain; yellow color with a large amount; secondary symptoms: dyspareunia pain; low heat; increased menstrual abdominal pain, prolonged menstrual period, excessive menstrual flow, and blood clots; yellow urine; dry stool or loose stool; bitter taste and dry throat; drowsiness of the limbs, purple and dark tongue with ecchymosis, yellow and greasy coating and slippery and rapid pulse. The main symptoms are necessary, the secondary symptoms have at least 2 items, and the syndrome of damp-heat stasis can be diagnosed by consulting tongue and pulse.
1.3 inclusion criteria
(1) Meets the diagnostic criteria; (2) age 24-45 years old; (3) can tolerate enema treatment; (4) the cognition and communication are free from disorder, and can be matched with related investigation and diagnosis and treatment.
1.4 exclusion criteria
(1) Other pelvic diseases such as pelvic tuberculosis, tumor and the like are combined; (2) it is combined with other system diseases and has bad preference for smoking and drinking.
2 methods of treatment
2.1 control group
Levofloxacin hydrochloride tablets are administered 0.4 g each time, 1 time a day, and metronidazole tablets (Huarun Shuanghe Jimin medicine each time 0.4 g each time, 1 time a day, and 14 d continuous for 1 treatment course.
2.2 viewing group
The enema prescription for resolving dampness and removing blood stasis is administered on the basis of the control group. Adding 100-150 mL of warm water into the medicinal granules, soaking the medicinal granules slightly above the body temperature without scalding, placing the medicinal granules into an enema bag, ordering the patient to sit on the side after the patient empties and urinates, raising the buttocks by 5-10 cm, lubricating the disposable tube, slightly inserting the disposable tube into anus 14-15 cm, dripping the disposable tube at the speed of 60-70 drops per minute, ordering the patient to continue to sit on the side for 20-30 min after the completion, and keeping the patient on the side for 1 time every day, wherein the continuous period of 14-d is 1 treatment course.
3 observation of curative effect
3.1 observations index
3.1.1 Main outcome index
(1) The pelvic cavity sign scale (McCormack) is adopted to evaluate abdominal tenderness or rebound pain, uterine tenderness, cervical lifting and swinging pain, accessory area tenderness and the like before and after treatment for 0-3 minutes, and the higher the score is, the more pain is represented.
(2) The pain emotion before and after the treatment was evaluated with the McGill pain scale in 0 to 3 points, and a higher score indicates a more painful pain.
3.1.2 Secondary outcome measures
(1) And (3) evaluating the scores of the traditional Chinese medicine symptoms before and after two groups of treatments, wherein the higher the score is, the more serious the symptoms of the patient are prompted.
(2) Inflammation level: the level of Interleukin 6 (IL-6) was detected by ELISA.
3.2 evaluation of safety
Is effective in treating the safety problems (such as adverse drug reaction, etc.) in the treatment of patients in time.
3.3 statistical treatment
Statistical analysis was performed using SPSS26.0 software, and the mean ± standard was used for normal distribution of the metrology data
Differences (x + -s) indicate that the intra-group comparison uses paired sample t-test, and the inter-group comparison uses two independent sample t-tests; count data is expressed as frequency or percent (%), χ is used 2 And (5) checking. To be used forPA difference of < 0.05 is statistically significant. (the corner mark (1) has statistical significance in comparison before and after the group, and the corner mark (2) has statistical significance in comparison after the treatment between the groups)
3.4 results
(1) Comparison of general data for two groups of patients
The common data such as age, pelvic cavity sign scale, mcGill pain scale, chinese medicine syndrome integral, serum IL-6 level and the like of two groups of patients are not statistically significantP> 0.05), with comparability, see table 1.
Table 1 comparison of general data for two groups of patients
(2) Comparison of pelvic sign scales and McGill pain scales before and after treatment of two groups of patients
The integral of the pelvic cavity sign scales of the two groups of patients after treatment is reduced compared with that before treatmentP<0.05 And observe the pelvic sign scale after group treatmentThe integral is obviously lower than that of the control groupP<0.05 A) is provided; the McGill pain scale after both groups of treatments was significantly lower than before treatment @P<0.05 And the McGill pain scale of the observation group is obviously reduced compared with that of the control groupP<0.05 See table 2).
Table 2 comparison of the pelvic signs and McGill pain scales before and after treatment for two groups of patients
Note that compared with the group before treatment, (1) P<0.05, compared with the treatment of the control group, (2) P<0.05。
(3) Traditional Chinese medicine syndrome integral comparison before and after treatment of two groups of patients
The traditional Chinese medicine syndrome integration of two groups of patients after treatment is reduced compared with that before treatmentP<0.05 Observation that the traditional Chinese medicine syndrome score of the sub-group after treatment is lower than that of the control groupP<0.05). Details are shown in Table 3.
Table 3 comparison of the integral of the symptoms of chinese medicine before and after treatment of two groups of patients
Note that compared with the group before treatment, (1) P<0.05, compared with the treatment of the control group, (2) P<0.05。
(4) Serum inflammation level comparison of two groups of patients
Serum inflammation index IL-6 of two groups of patients after treatment is reduced compared with that before treatmentP<0.05 Observation that the traditional Chinese medicine syndrome score of the sub-group after treatment is lower than that of the control groupP<0.05). Details are shown in Table 4.
Table 4 comparison of serum inflammation levels in two groups of patients
Note that compared with the group before treatment, (1) P<0.05, compared with the treatment of the control group, (2) P<0.05。
conclusion(s)
The research result shows that the enema prescription for resolving dampness and removing stasis can effectively reduce the scores of the pelvic cavity sign scale and the McGill pain scale of a patient with chronic pelvic inflammatory disease, improve the clinical symptoms of damp-heat stasis of the patient, reduce the serum inflammation level and relieve the symptoms of the chronic pelvic inflammatory disease.
Claims (6)
1. The clysis formula for resolving dampness and removing stasis is characterized by comprising 1-20 parts of patrinia herb, 1-20 parts of dandelion, 1-30 parts of polygonum cuspidatum, 1-20 parts of spatholobus stem, 1-20 parts of ligusticum wallichii, 1-20 parts of red sage root, 1-20 parts of rhizoma curcumae, 1-20 parts of rhizoma atractylodis, 1-20 parts of red paeony root, 1-30 parts of wrinkled gianthyssop and 1-30 parts of raw astragalus mongholicus.
2. The clysis formula for resolving dampness and removing stasis according to claim 1, which is characterized by comprising 10 parts of patrinia herb, 10 parts of dandelion, 15 parts of giant knotweed, 10 parts of suberect spatholobus stem, 10 parts of szechuan lovage rhizome, 10 parts of red sage root, 10 parts of zedoary, 10 parts of swordlike atractylodes rhizome, 10 parts of red paeony root, 15 parts of wrinkled gianthyssop herb and 15 parts of raw astragalus root.
3. The clysis formula for resolving dampness and removing stasis is characterized by comprising 1-20 parts of patrinia herb, 1-20 parts of dandelion, 1-30 parts of polygonum cuspidatum, 1-20 parts of spatholobus stem, 1-20 parts of ligusticum wallichii, 1-20 parts of red sage root, 1-20 parts of rhizoma curcumae, 1-20 parts of rhizoma atractylodis, 1-20 parts of red paeony root, 1-30 parts of wrinkled gianthyssop, 1-30 parts of radix astragali, 1-20 parts of Luo Mailiang dragon and 2-10 parts of Chinese medicine.
4. The clysis formula for resolving dampness and removing stasis according to claim 3, which is composed of 10 parts of patrinia herb, 10 parts of dandelion, 15 parts of giant knotweed, 10 parts of suberect spatholobus stem, 10 parts of szechuan lovage rhizome, 10 parts of red sage root, 10 parts of zedoary, 10 parts of swordlike atractylodes rhizome, 10 parts of red paeony root, 15 parts of wrinkled gianthyssop herb, 15 parts of raw astragalus root, 10 parts of Luo Mailiang dragon and 10 parts of Chinese boat.
5. A rectal administration preparation based on the dampness-resolving stasis-removing enema prescription according to claim 1 or 3, which is characterized by further comprising pharmaceutically acceptable auxiliary materials, and is prepared into the rectal administration preparation.
6. Use of the dampness-resolving stasis-removing enema formulation according to claim 1 or 3 in the preparation of a medicament for the treatment of chronic pelvic inflammatory disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311451517.8A CN117159674B (en) | 2023-11-03 | 2023-11-03 | Gynecological traditional Chinese medicine composition for treating damp-heat stasis syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311451517.8A CN117159674B (en) | 2023-11-03 | 2023-11-03 | Gynecological traditional Chinese medicine composition for treating damp-heat stasis syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117159674A CN117159674A (en) | 2023-12-05 |
| CN117159674B true CN117159674B (en) | 2024-01-09 |
Family
ID=88941676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311451517.8A Active CN117159674B (en) | 2023-11-03 | 2023-11-03 | Gynecological traditional Chinese medicine composition for treating damp-heat stasis syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117159674B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117205231B (en) * | 2023-11-08 | 2024-02-02 | 云南中医药大学 | Traditional Chinese medicine composition for nourishing blood and increasing film and preparation thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631589A (en) * | 2012-03-31 | 2012-08-15 | 付正英 | Penyanxiao enema and preparation method thereof |
| CN102631641A (en) * | 2012-04-26 | 2012-08-15 | 卢培玲 | Clysis liquid for treating pelvic inflammation |
| CN103721131A (en) * | 2013-12-30 | 2014-04-16 | 青岛恒波仪器有限公司 | Traditional Chinese medicinal suppository for treating female chronic pelvic inflammation and preparation method thereof |
| CN103908628A (en) * | 2014-03-17 | 2014-07-09 | 於永梅 | A traditional Chinese medicine enema medicament used for treating chronic pelvic inflammation and a preparing method thereof |
| CN104840884A (en) * | 2015-05-22 | 2015-08-19 | 郭立新 | Traditional Chinese medicinal preparation for treating chronic pelvic inflammatory disease |
| CN105749037A (en) * | 2016-03-30 | 2016-07-13 | 宜都市中医医院 | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease and preparation method and application thereof |
| CN109620786A (en) * | 2019-01-25 | 2019-04-16 | 昆明远方生物制品有限公司 | A kind of Anti-hair loss plant hair-growing composition and preparation method thereof |
| CN109908299A (en) * | 2019-04-08 | 2019-06-21 | 黑龙江双兰星制药有限公司 | It is a kind of for treating the bowel lavage medicament of pelvic inflammatory disease |
| CN110251593A (en) * | 2019-08-07 | 2019-09-20 | 深圳市福田区风湿病专科医院 | A kind of improvement nano traditional Chinese medicine suppository and preparation method thereof for treating chronic pelvic inflammatory disease |
-
2023
- 2023-11-03 CN CN202311451517.8A patent/CN117159674B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631589A (en) * | 2012-03-31 | 2012-08-15 | 付正英 | Penyanxiao enema and preparation method thereof |
| CN102631641A (en) * | 2012-04-26 | 2012-08-15 | 卢培玲 | Clysis liquid for treating pelvic inflammation |
| CN103721131A (en) * | 2013-12-30 | 2014-04-16 | 青岛恒波仪器有限公司 | Traditional Chinese medicinal suppository for treating female chronic pelvic inflammation and preparation method thereof |
| CN103908628A (en) * | 2014-03-17 | 2014-07-09 | 於永梅 | A traditional Chinese medicine enema medicament used for treating chronic pelvic inflammation and a preparing method thereof |
| CN104840884A (en) * | 2015-05-22 | 2015-08-19 | 郭立新 | Traditional Chinese medicinal preparation for treating chronic pelvic inflammatory disease |
| CN105749037A (en) * | 2016-03-30 | 2016-07-13 | 宜都市中医医院 | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease and preparation method and application thereof |
| CN109620786A (en) * | 2019-01-25 | 2019-04-16 | 昆明远方生物制品有限公司 | A kind of Anti-hair loss plant hair-growing composition and preparation method thereof |
| CN109908299A (en) * | 2019-04-08 | 2019-06-21 | 黑龙江双兰星制药有限公司 | It is a kind of for treating the bowel lavage medicament of pelvic inflammatory disease |
| CN110251593A (en) * | 2019-08-07 | 2019-09-20 | 深圳市福田区风湿病专科医院 | A kind of improvement nano traditional Chinese medicine suppository and preparation method thereof for treating chronic pelvic inflammatory disease |
Non-Patent Citations (9)
| Title |
|---|
| "冲为血海"的理论基础及其在妇科疾病中的应用探讨;刑利威，等;云南中医学院学报;第45卷(第05期);6-9 * |
| Acupuncture Improves Endometrial Angiogenesis by Activating PI3K/AKT Pathway in a Rat Model with PCOS;Liwei Xing，等;Evid Based Complement Alternat Med.;第1790041篇第1-15页 * |
| 中医治疗慢性盆腔炎的护理体会;熊丽萍;云南中医中药杂志;第34卷(第04期);80-81 * |
| 傣医辨证治疗纳勒冒沙么(月经失调)初探;玉腊波;中国民族民间医药;第25卷(第01期);5 * |
| 克林霉素联合中药灌肠治疗慢性盆腔炎的临床观察;庄秀峰;中国医学创新;第09卷(第24期);39-40 * |
| 理气消瘀汤加灌肠治疗慢性盆腔痛42例;李宇青;福建中医药;第47卷(第01期);41-42 * |
| 红藤败酱汤保留灌肠配合盆腔理疗治疗慢性盆腔炎的临床疗效分析;艳珠，等;中国现代医生;第53卷(第28期);129-131 * |
| 自拟清热逐秽饮保留灌肠联合抗生素对盆腔炎性疾病后遗症的疗效研究;邵美华，等;辽宁中医杂志;1-7 * |
| 辨证论治Fitz-Hugh-Curtis综合征;杨荣静，等;中国实验方剂学杂志;第22卷(第17期);187-192 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117159674A (en) | 2023-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117159674B (en) | Gynecological traditional Chinese medicine composition for treating damp-heat stasis syndrome | |
| CN101342353A (en) | Traditional Chinese medicine preparation for treating barrenness and preparation method thereof | |
| CN103585378A (en) | A Chinese medicinal composition for treating female infertility, and its preparation method | |
| CN102836409B (en) | Traditional Chinese medicine for treating postpartum lochiorrhea and preparation method | |
| CN101129868A (en) | Orally taken traditional Chinese medicine composition for treating chronic pelvic inflammatory disease | |
| CN103638511A (en) | Postpartum stasis removing particles | |
| CN103349766B (en) | Pharmaceutical composition for endless postpartum lochia | |
| CN104435519B (en) | A kind of pharmaceutical composition for treating primary dysmenorrhea | |
| CN1843491A (en) | Medicine composition for treating endometriosis | |
| CN101422573A (en) | Medicine composition for treating postpartum disease | |
| CN102631641A (en) | Clysis liquid for treating pelvic inflammation | |
| CN104721418A (en) | Pharmaceutical composition for treating gynecological inflammation and preparation method and use thereof | |
| CN103893671A (en) | Pharmaceutical composition for treating hysteromyoma | |
| CN112546178A (en) | Traditional Chinese medicine preparation for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN103432270A (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN105079633A (en) | Traditional Chinese medicine composition capable of activating blood circulation to remove blood stasis and removing cumulation and stasis | |
| CN103301373B (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN104984020A (en) | Traditional Chinese medicinal preparation for treating hysteromyoma, and preparation method thereof | |
| CN101366878A (en) | Traditional Chinese medicine for female acyesis and aphoria and preparation method thereof | |
| CN108671186A (en) | A kind of Chinese medicinal enema for treating chronic pelvic inflammatory disease | |
| CN101601832A (en) | A kind of medicine for the treatment of chronic pelvic inflammatory disease and preparation method thereof | |
| CN105477264A (en) | Medicinal preparation for treating urethral syndrome | |
| CN105663583A (en) | Traditional Chinese medicine composition for treating female urinary tract infection and preparation method thereof | |
| CN104740582A (en) | Pharmaceutical preparation for removing blood stasis after delivery as well as detection and detection method for pharmaceutical preparation | |
| CN106266970B (en) | A kind of Chinese medicine composition treated production and cause endometritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |